CClinicalTrials.gg
RecruitingNCT07324733Updated Jul 29, 2026

Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET Imaging

An interventional study of ⁶⁸Ga-PSMA PET/CT and ⁶⁸Ga-FAPI PET/CT in Primary Sjögren Syndrome and PET, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Oct 2023, registered Dec 2025).
  • Started Oct 2023; still recruiting 3 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Primary Sjögren's syndrome (pSS) is a chronic autoimmune exocrinopathy characterized by lymphocytic infiltration, progressive destruction of salivary gland acini, and varying degrees of functional impairment and fibrosis. Conventional imaging provides limited ability to simultaneously evaluate glandular function and inflammatory activity, leading to challenges in disease staging and treatment decision-making. This study explores a conceptual dual-tracer imaging framework using PSMA PET and FAPI PET to delineate complementary biological processes in pSS.

Read the detailed description

Based on current evidence, salivary gland acinar cells physiologically express PSMA; thus, reduced PSMA uptake may reflect loss of functional parenchyma in patients with pSS. In contrast, activated fibroblasts markedly express FAP, and increased FAPI uptake correlates with ongoing inflammation and fibroblast-driven remodeling. We hypothesize that within the same gland, functional decline (PSMA↓) and inflammatory activity (FAPI↑) may coexist and exhibit a negative correlation, forming a paired imaging biomarker that captures both pathological dimensions. By integrating these two signals into a combined PSMA/FAPI Index, this approach may enable more precise characterization of the "function-inflammation" spectrum in pSS, providing a noninvasive tool for disease staging, monitoring, and potentially predicting therapeutic response.

02

Conditions studied

  • Primary Sjögren Syndrome
  • PET
03

In context

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,115 studies on the registry; 463 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18-80 years;
  • Fulfillment of the 2016 ACR-EULAR Classification Criteria for pSS at enrollment. OR diagnosis of a solid tumor scheduled for FAPI PET imaging

Exclusion criteria

Exclusion Criteria:

  • Combined with tumors or other connective tissue diseases (for SS group);
  • Patients who are currently using hormones/biological agents (for both groups);
  • Pregnancy or lactation
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    pSS Dual-Tracer Imaging Arm (PSMA + FAPI PET)

    This arm includes patients diagnosed with primary Sjögren's syndrome. All participants undergo both PSMA PET and FAPI PET imaging. The PSMA PET scan is used to assess the functional integrity of salivary gland acinar cells, while the FAPI PET scan evaluates inflammatory and fibroblast activity within the same glands. The purpose of this arm is to characterize the functional-inflammatory relationship in pSS and to develop the combined PSMA/FAPI Index for disease staging and activity assessment.

    Diagnostic Test: ⁶⁸Ga-PSMA PET/CT · Diagnostic Test: ⁶⁸Ga-FAPI PET/CT

  • Active comparator
    Prostate Cancer PSMA-Only Comparator Arm

    This arm consists of patients with prostate cancer who undergo PSMA PET imaging only, representing a population with preserved or physiologic salivary gland PSMA uptake. These scans serve as a reference group for establishing normal or baseline PSMA expression in salivary glands. This comparator arm allows differentiation between disease-related PSMA reduction in pSS and normal tracer distribution observed in patients without salivary gland pathology.

    Diagnostic Test: ⁶⁸Ga-PSMA PET/CT

Interventions

  • Diagnostic test⁶⁸Ga-PSMA PET/CT

    PSMA PET imaging performed for clinical evaluation in prostate cancer patients, used as a comparator for physiologic salivary gland PSMA uptake.

  • Diagnostic test⁶⁸Ga-FAPI PET/CT

    FAPI PET imaging to assess inflammatory activity (FAPI) in patients with primary Sjögren's syndrome.

06

What researchers measure

Primary outcomes

  1. Difference in Salivary Gland PSMA Uptake Across Groups

    Quantitative comparison of PSMA PET uptake parameters (SUVmax, SUVmean) of the parotid glands among three groups: pSS patients, individuals with normal salivary glands, and prostate cancer patients.

    Time frame: Baseline

Secondary outcomes

  1. Multiglandular PSMA Uptake Comparison

    Evaluation of PSMA PET uptake (SUVmax, SUVmean) in the parotid, submandibular, and lacrimal glands across the same study groups.

    Time frame: Baseline

  2. Correlation Between PSMA Uptake and Clinical Indicators

    Correlation of salivary gland PSMA SUV values with clinical, immunological, and functional markers of pSS, including ESR, CRP, IgG, RF, anti-SSA/SSB titers, unstimulated whole salivary flow rate, sialography findings, ESSDAI, and ESSPRI scores.

    Time frame: Baseline

  3. Quantitative and Spatial Relationship Between PSMA and FAPI Uptake Definition

    1. Quantitative correlation: Association between PSMA SUV and FAPI SUV in the same glands. 2. Spatial co-localization: Overlap or complementarity of low-PSMA and high-FAPI regions within individual glands using image fusion and voxel-based analysis (e.g., Dice coefficient).

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07324733
Lead sponsor
Peking Union Medical College Hospital
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Oct 1, 2023
Primary completion
Jan 30, 2026
Completion
Sep 30, 2026 (estimated)
Last update
Jul 29, 2026

Study contacts

Zhaohui Zhu, MD
Contact
13611093752@163.com
13611093752
Jiarou Wang, MD
Contact
ChristinaWang97@163.com
13628477019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion